Data that were presented during the 2021 ASCO Annual Meeting shed light on new therapeutic strategies, and treatment considerations that are expanding the paradigms of gastrointestinal malignancies.
Refining treatment is not only a key aim of research in breast cancer but a greater possibility in the clinic with neoadjuvant and adjuvant PARP inhibitors, HER2 monoclonal antibodies, and greater stratification of genomic risk.
The novel agents olutasidenib, brexucabtagene autoleucel, and ponatinib demonstrated encouraging data at the 2021 ASCO Annual Meeting in leukemias, renewing hope in the ability to salvage patients with relapsed/refractory disease.
Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.
Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.
Although the armamentarium of multiple myeloma is rich with available treatment options, novel triplet regimens, maintenance therapies, and targets beyond BCMA are further expanding the paradigm across the newly diagnosed, early-relapse, and late-relapse disease states.
Several studies presented during the 2021 ASCO Annual Meeting highlighted the severity of racial and ethnic disparities that exist in the treatment of patients with cancer, ranging from clinical trial enrollment to routine care visits.
Practice-validating trials in cervical cancer, endometrial cancer, and ovarian cancer were the focus of the 2021 ASCO Annual Meeting in gynecologic oncology, each carrying relevant implications on extended therapy, surveillance, and biomarker testing.
Dawn L. Hershman, MD, MS, spotlights important data pertaining to cancer care delivery, prevention, symptom management, and survivorship that were presented at the 2020 ASCO Virtual Scientific Program.
Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention.
The field of gynecologic oncology gained a number of important updates at the 2020 ASCO Virtual Scientific Program. As part of the ASCO Direct Highlights webcast, Jubilee Brown, MD, provided insight on key trials that were presented at the program.
The downstream effects of the coronavirus disease 2019 on patients with cancer have become apparent over the past few months, and the onus is on the field to provide clinical guidance on best practices in the absence of definitive data.
There was no shortage of exciting developments at the 2020 ASCO Virtual Scientific Program in multiple myeloma. Peter Voorhees, MD, explained all of the pivotal data in myeloma therapeutics in a virtual presentation during the 2020 ASCO Direct Highlights webcast.
A number of influential clinical trials were presented during the 2020 ASCO Virtual Scientific Program, 8 of which Stephen Liu, MD, discusses in depth in a virtual presentation during the 2020 ASCO Direct Highlights webcast.